Please Scroll Down to See Forums Below
How to install the app on iOS

Follow along with the video below to see how to install our site as a web app on your home screen.

Note: This feature may not be available in some browsers.

napsgear
genezapharmateuticals
domestic-supply
puritysourcelabs
RESEARCHSARMSUGFREAKeudomestic
napsgeargenezapharmateuticals domestic-supplypuritysourcelabsRESEARCHSARMSUGFREAKeudomestic

L-Carnitine

BileStew

New member
What's the deal with this stuff? I have a friend who was drinking it from the bottle before one of our I games and I asked him what it was and about it. All he said was it was a fat burner. I asked him how it worked and he had no clue.

Can someone tell me if this is an effective fat burner or what it is intended for.

Thanks
 
It's crap.

--------------------------------

Carnitine and physical exercise.

Heinonen OJ.

Department of Clinical Chemistry, Turku University Hospital, Finland.

Carnitine plays a central role in fatty acid (FA) metabolism. It transports long-chain fatty acids into mitochondria for beta-oxidation. Carnitine also modulates the metabolism of coenzyme-A (CoA). It is not surprising that the use of supplementary carnitine to improve physical performance has become widespread in recent years, although there is no unequivocal support to this practice. However, critical reflections and current scientific-based knowledge are important because the implications of reduced or increased carnitine concentrations in vivo are not thoroughly understood. Several rationales have been forwarded in support of the potential ergogenic effects of oral carnitine supplementation. However, the following arguments derived from established scientific observations may be forwarded: (i) carnitine supplementation neither enhances FA oxidation in vivo or spares glycogen or postpones fatigue during exercise. Carnitine supplementation does not unequivocally improve performance of athletes; (ii) carnitine supplementation does not reduce body fat or help to lose weight; (iii) in vivo pyruvate dehydrogenase complex (PDC) is fully active already after a few seconds of intense exercise. Carnitine supplementation induces no further activation of PDC in vivo; (iv) despite an increased acetyl-CoA/free CoA ratio, PDC is not depressed during exercise in vivo and therefore supplementary carnitine has no effect on lactate accumulation; (v) carnitine supplementation per se does not affect the maximal oxygen uptake (VO2max); (vi) during exercise there is a redistribution of free carnitine and acylcarnitines in the muscle but there is no loss of total carnitine. Athletes are not at risk for carnitine deficiency and do not have an increased need for carnitine. Although there are some theoretical points favouring potential ergogenic effects of carnitine supplementation, there is currently no scientific basis for healthy individuals or athletes to use carnitine supplementation to improve exercise performance.

PMID: 8857706 [PubMed - indexed for MEDLINE]

---------------------------------

Effect of L-carnitine on weight loss and body composition of rats fed a hypocaloric diet.

Brandsch C, Eder K.

Institute of Nutritional Sciences, University of Halle, Germany.

BACKGROUND/AIMS: Several studies have been published in recent years which suggest that L-carnitine supplementation can influence the lipid metabolism in some species and can also affect body composition of growing animals. Only few results are available so far on the effect of L-carnitine supplementation on weight reduction and body composition of animals fed an energy-deficient diet. The aim of this study was therefore to investigate whether L-carnitine supplementation combined with an energy-deficient diet can influence weight development and body composition. METHODS: An experiment was conducted with 36 rats with an initial body weight of about 460 g. One-third of the rats were killed, the remainder were divided into two groups (control group, treated group) and fed a semi synthetic diet at an energy level of about half of the rats' maintenance requirement. The basal diet was essentially carnitine-free. The diet of the treated group was supplemented with L-carnitine (5 g/kg). The feeding period extended over 23 days. Experimental parameters were weight loss, composition of carcass and weights of the fat pads surrounding the kidneys, intestine and testes; several clinico-chemical plasma parameters were also determined. RESULTS: As was to be expected, the rats lost a considerable amount of weight on the energy-reduced diet. At the same time a shift occurred in the ratio of fat to protein in favour of protein in the carcass, leading to a marked reduction of body fat levels and a slight reduction of protein levels. There were, however, no significant differences between the control group and the treated group (with L-carnitine supplementation) with regard to any of these parameters. The clinico-chemical parameters measured in plasma (glucose, triglycerides, total cholesterol, free fatty acids, 3-hydroxybutyric acid) also showed no differences between the groups. CONCLUSIONS: The rat model used here did not show a positive effect of L-carnitine supplementation on weight loss and body composition of rats fed an energy-deficient diet. The animals' endogenous carnitine synthesis was obviously adequate to ensure efficient beta-oxidation of fatty acids during the catabolic phase. Copyright 2002 S. Karger AG, Basel

PMID: 12378044 [PubMed - indexed for MEDLINE]

-------------------------------------------------

1: Int J Sport Nutr Exerc Metab. 2000 Jun;10(2):199-207. Related Articles, Links


L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women.

Villani RG, Gannon J, Self M, Rich PA.

Department of Human Biology and Movement Science, Royal Melbourne Institute of Technology, Melbourne, Victoria, 3083, Australia.

L-Carnitine (L-C) transports fatty acids into mitochondria for oxidation and is marketed as a weight loss supplement. In a double-blind investigation to test the weight loss efficacy of L-C, 36 moderately overweight premenopausal women were pair matched on Body Mass Index (BMI) and randomly assigned to two groups (N = 18). For 8 weeks the L-C group ingested 2 g twice daily of L-C, while the placebo (P) group ingested the same amount of lactose. All subjects walked for 30 min (60-70% maximum heart rate) 4 days/week. Body composition, resting energy expenditure (REE) and substrate utilization were estimated before and after treatment. For the subjects who completed the study (15 P, 13 L-C), no significant changes in mean total body mass (TBM), fat mass FM, and resting lipid utilization occurred over time, nor were there any significant differences between groups for any variable. Conversely REE increased significantly for all subjects, but no between group differences existed. Five of the L-C group experienced nausea or diarrhea and consequently did not complete the study. Eight weeks of L-C ingestion and walking did not significantly alter the TBM or FM of overweight women, thereby casting doubt on the efficacy of L-C supplementation for weight loss.

Publication Types:
Clinical Trial
Randomized Controlled Trial

PMID: 10861338 [PubMed - indexed for MEDLINE]

------------------------------------------------
 
Acetyl L-Carnitine is a great supplement.

If you know how to use it, it works very well.

~SC~
 
Here is some info on ALC...

~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Acetyl L-Carnitine

ALC improves both Short-Term Memory and Long-Term Memory.

ALC improves Mood [ALC improves Mood in 53% of healthy subjects].

Acetyl L-Carnitine retards some aspects of the Aging Process in the Skin:

ALC improves the reaction times of people afflicted with Cerebral Insufficiency.

ALC (2-4 grams per day) improves walking distance without Pain in people afflicted with Intermittent Claudication.

ALC prevents the age-related impairment of Eyesight (by protecting the Neurons of the Optic Nerve and the Occipital Cortex of the Brain.

ALC enhances the ability of Macrophages to function as Phagocytes.

ALC improves Athletic Performance [ALC given prior to Exercise increased the maximum running speed of animals].

ALC enhances the function of Cytochrome Oxidase (an essential enzyme of the Electron Transport System (ETS).

ALC improves the Energy metabolism of Neurons (by enhancing the transport of Medium-Chain Saturated Fatty Acids and Short-Chain Saturated Fatty Acids across the Cell Membranes of Neurons into the Mitochondria).

ALC inhibits the damage caused by Hypoxia.
ALC transports Lipids into the Mitochondria of Cells.

ALC improves mood and memory in people with Age Associated Memory Impairment.

ALC improves Mental Function where Alcohol induced cognitive Impairment exists.

ALC increases Alertness.

Acetyl-L-Carnitine inhibits the deterioration in Mental Function associated with Alzheimer’s Disease and slows the progression of Alzheimer’s Disease [people afflicted with Alzheimer’s Disease exhibited significantly less deterioration in Mental Function following the administration of supplemental ALC for 12 months. This finding was verified by using nuclear magnetic resonance on the subjects].

ALC increases Alertness in people afflicted with Alzheimer's Disease - 2,500-3,000 mg per day for 3 months].
ALC inhibits the toxicity of Amyloid-Beta Protein (ABP) to Neurons.

ALC improves Attention Span in people afflicted with Alzheimer's Disease.

ALC improves Short Term Memory in people afflicted with Alzheimer's Disease.

High concentrations of ALC are naturally present in various regions of the Brain.
ALC reverses the age-related decline that occurs in Cholinergic Receptors (i.e. the Receptors that receive Acetylcholine).

ALC improves (eye to hand) Coordination [supplemental ALC @ 1.5 grams per day for 30 days improved eye to hand coordination in healthy, sedentary subjects by a factor of 300-400%].

ALC improves the Interhemispheric Flow of Information across the Corpus Callosum of the Brain.

ALC retards the decline in the number of Dopamine Receptors that occurs in tandem with the Aging Process and (more rapidly) with the onset of Parkinson's Disease.

ALC enhances the release of Dopamine from Dopaminergic Neurons and improves the binding of Dopamine to Dopamine Receptors.

ALC can prevent the destruction of Dopamine Receptors by MPTP (a neurotoxin capable of causing Parkinson's Disease via Dopaminergic Receptor death.

ALC improves Attention Span and Memory in people afflicted with Down’s Syndrome.

ALC retards the inevitable decline in the number of Glucocorticoid Receptors that occurs in tandem with the Aging Process.

ALC enhances the recovery of people afflicted with Hemiplegia (Paralysis of one side of the body) and improves their Mood and Attention Span.

ALC retards the age-related deterioration of the Hippocampus [research - rats].

Acetyl-L-Carnitine (ALC) improves Learning ability [women aged 22 - 27 were supplemented with ALC for 30 days. Complex video game tests before and after supplementation concluded that supplemental ALC caused large increases in speed of Learning, speed of reaction and reduction in errors].

ALC inhibits (and possibly reverses) the degeneration of Myelin Sheaths that occurs in tandem with the progression of the Aging Process [scientific research - hyperglycemic mice treated with ALC for 16 weeks exhibited improved nerve conduction velocity and exhibited thicker Myelin Sheaths and larger myelinated Nerve Fibers].

ALC retards the inevitable decline in the number of Nerve Growth Factor (NGF) Receptors that occurs in tandem with the Aging Process.

ALC stimulates and maintains the growth of new Neurons within the Brain (both independently of Nerve Growth Factor (NGF) and as a result of preserving NGF) and helps to prevent the death of existing Neurons [ALC inhibits Neuron death in the Striatal Cortex, Prefrontal Cortex and the Occipital Cortex of the Brain].

ALC inhibits the degeneration of Neurons that is implicit in Neuropathy.

ALC rejuvenates and increases the number of N-Methyl-D-Aspartate Receptors (NMDA Receptors) in the Brain [even a single dose of ALC increases the number of functional NMDA Receptors]:

ALC protects the NMDA Receptors in the Brain from the natural decline that occurs in tandem with the Aging Process [research - animals].

ALC is presently being researched as a treatment for Parkinson's Disease.

ALC inhibits the loss of Vision, degeneration of Neurons and damage to the Retina associated with Retinopathy (including Diabetic Retinopathy).

ALC improves the quality of Sleep and reduces the quantity of Sleep required.

ALC improves Spatial Memory (an aspect of Short Term Memory that involves remembering one’s position in space).

ALC inhibits the excessive release of Cortisol in response to Stress and inhibits the depletion of Luteinising Hormone Releasing Hormone (LHRH) and Testosterone that occurs as a result of excessive Stress.

ALC improves Verbal Fluency.

ALC enhances the function of Cytochrome Oxidase (also called Complex IV) - an essential enzyme of the Electron Transport System.

ALC normalizes Beta-Endorphin levels.
ALC reduces Stress-induced Cortisol release [research - animals].

ALC prevents the depletion of Luteinising Hormone Releasing Hormone (LHRH) caused by exposure to excessive Stress.

ALC retards the decline in the production of Nerve Growth Factor (NGF) that occurs in tandem with the Aging Process.

ALC increases plasma Testosterone levels (via its influence on Acetylcholine neurotransmission in the Striatal Cortex of the Brain) and prevents the depletion of Testosterone caused by exposure to excessive Stress [research - rats].

ALC increases the body's levels of circulating Thyrotrophin.

ALC facilitates the production of Adenosine Triphosphate (ATP) [research - animals].

ALC "shuttles" Long Chain Fatty Acids between the Cytosol and the Mitochondria of Cells.

ALC facilitates both the release and synthesis of Acetylcholine.

ALC's ability to increase the synthesis of Acetylcholine occurs as a result of it donating its Acetyl group towards the production of Acetylcholine.

ALC increases the Brain's levels of Choline Acetylase (which in turn facilities the production of Acetylcholine).

ALC enhances the release of Dopamine from Dopaminergic Neurons and improves the binding of Dopamine to Dopamine Receptors.

References

De Falco, F. A., et al. Effect of the chronic treatment with L-acetylcarnitine in Down’s syndrome. Clin Ther. 144:123-127, 1994.

Bowman, B. Acetyl-carnitine and Alzheimer’s disease. Nutr Rev. 50:142-144, 1992.

Bruno, G., et al. Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides. Alzheimer Dis Assoc Disord (USA). 9(3):128-131, 1995.

Calvani, M., et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer’s disease. Annals of the New York Academy of Sciences (USA). 663:483-486, 1993.

Carta, A., et al. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer’s Disease? Annals of the New York Academy of Sciences (USA. 640:228-232, 1991.

Guarnaschelli, C., et al. Pathological brain ageing: evaluation of the efficacy of a pharmacological aid. Drugs under Experimental and Clinical Research. 14(11):715-718, 1988.

Passeri, M., et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. International Journal of Clinical Pharmacology Research. 10(1-2):75-79, 1990.

Pettegrew, J. W., et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging. 16:1-4, 1995.

Rai, G., et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer’s dementia. Current Medical Research and Opinion. 11(10):638-647, 1989.

Sano, M., et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s disease. Arch Neurol. 49:1137-1141, 1992.

Sinforiani, E., et al. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. International Journal of Clinical Pharmacology Research. 10(1-2):69-74, 1990.

Spagnoli, A. U., et al. Long-term acetyl-l-carnitine treatment in Alzheimer’s disease. Neurology. 41(11):1726-1732, 1991.
 
Some more:

College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL 32307, USA.

Acetyl-L-carnitine (ALCAR) plays an integral role in the transport of long chain fatty acids across the inner mitochondrial membrane for oxidative phosphorylation. In non-human primates, administration of ALCAR was reported to prevent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurological injury to the substantia nigra. The present study investigates the effects of ALCAR against the toxicity of 1-methyl-4-phenylpyridinium (MPP(+)), the neurotoxic metabolite of MPTP, in murine brain neuroblastoma cells. MPP(+), a potent mitochondrial toxin, induced a dose-dependent reduction in mitochondrial oxygen consumption and cell viability, corresponding to an accelerated rate of cellular glucose utilization. Treatment with ALCAR, but not L-carnitine, prevented MPP(+) toxicity and partially restored intracellular ATP concentrations, but did not reverse the MPP(+)-induced loss of mitochondrial oxygen consumption. These data indicate that protective effects are independent of oxidative phosphorylation. ALCAR had a substantial glucose sparing effect in both controls and MPP(+)-treated groups, demonstrating a potential role in enhancing glucose utilization through glycolysis. Antagonizing the entry of fatty acids into the mitochondria, with either insulin or malonyl CoA, did not interfere with ALCAR protection against MPP(+). On the contrary, insulin potentiated the protective effects of ALCAR. In conclusion, these data indicate that ALCAR protects against MPP(+) toxicity, independent of mitochondrial oxidative capacity or beta-oxidation of fatty acids. In contrast, the protective effects of ALCAR appear to involve potentiation of energy derived from glucose through anaerobic glycolysis.

Blond-McIndoe Centre, Royal Free and University College Medical School, University Department of Surgery, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.

Peripheral nerve trauma remains a major cause of morbidity, largely due to the death of approximately 40% of innervating sensory neurons, and to slow regeneration after repair. Acetyl-L-carnitine (ALCAR) is a physiological peptide that virtually eliminates sensory neuronal death, and may improve regeneration after primary nerve repair. This study determines the effect of ALCAR upon regeneration after secondary nerve repair, thereby isolating its effect upon neuronal regenerative capacity. Two months after unilateral sciatic nerve division 1 cm nerve graft repairs were performed (n=5), and treatment with 50 mg/kg/day ALCAR was commenced for 6 weeks until harvest. Regeneration area and distance were determined by quantitative immunohistochemistry. ALCAR treatment significant increased immunostaining for both nerve fibres (total area 264% increase, P<0.001; percentage area 229% increase, P<0.001), and Schwann cells (total area 111% increase, P<0.05; percentage area 86% increase, P<0.05), when compared to no treatment. Regeneration into the distal stump was greatly enhanced (total area 2,242% increase, P=0.008; percentage area 3,034% increase, P=0.008). ALCAR significantly enhances the regenerative capacity of neurons that survive peripheral nerve trauma, in addition to its known neuroprotective effects.

Department of Applied Chemistry and Biotechnology, Faculty of Engineering, Yamanashi University, Yamanashi 400-8511, Japan.

In the present study, we examined the effects of acetyl-L-carnitine (ALC) on the brain lipid hydroperoxide level and on passive avoidance performance in senescence-acceleration-prone 8 mice (SAMP8). Mice were treated intraperitoneally with either saline or ALC (100 or 400 mg/kg) three times a week up to 4 months of age (starting at 3 weeks of age). In 4-month-old SAMP8, the deficit in learning and memory seen in saline-treated controls was significantly ameliorated in 400 mg/kg ALC-treated SAMP8, and the brain lipid hydroperoxide level was significantly lower in the 400 mg/kg ALC-treated group than in the saline-treated controls. Administration of 100 mg/kg ALC to SAMP8 did not have significant effect on learning and memory performance or on the brain lipid hydroperoxide level (by comparison with the saline-treated controls). These results suggest that ALC has antioxidant activity towards oxidative stress, and that the improvement in cognitive ability seen with ALC may occur through an amelioration of cellular dysfunction via an inhibition of the increase in lipid hydroperoxidation observed in the brain tissue of untreated SAMP8

Center for Neurobiology and Neurodegeneration Research, University of Massachusetts Lowell, Lowell, Massachusetts 01854, USA. [email protected]

Acetyl-L-carnitine (ALCAR), normally produced in mitochondria, is a precursor of acetyl-CoA in the tricarboxylic (TCA) cycle. Since mitochondrial compromise and ATP depletion have been considered to play a role in neuronal degeneration in Alzheimer's disease (AD), we examined whether ALCAR attenuated oxidative stress and/or ATP depletion after exposure of cells to beta-amyloid (Abeta), a neurotoxic peptide that accumulates in AD brain. Differentiated SH-SY-5Y human neuroblastoma cells were exposed for 2-24 h to 20 microM Abeta in the presence and absence of 50 microM ALCAR. ALCAR attenuated oxidative stress and cell death induced by Abeta neurotoxicity. Abeta depleted ATP levels, suggesting Abeta may induce neurotoxicity in part by compromising neuronal energy. ALCAR prevented ATP depletion; therefore, ALCAR may mediate its protective effect by buffering oxidative stress and maintaining ATP levels.




I'm taking in 3-4g's ALCar now...it's a truly great compound! If you're an athlete this is cardinal to combat innervation and harmful metabolites produced under stress (physical and mental, too)
 
Top Bottom